Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia

Inclusion Criteria: * Previously untreated T-lineage or precursor B-lineage ALL * Patients must have morphological proof of ALL and diagnosis must be made from bone marrow morphology with more than 25% blasts * Written informed consent * Treatment according to DCOG ALL 10 protocol Exclusion Criteria: * Mature B-lineage ALL * Patients with secondary ALL * Known allergy to any ASNase preparation * General health status according to Karnofsky / Lansky score \< 40% * Pre-existing known coagulopathy (e.g. haemophilia) * Pre-existing pancreatitis * Liver insufficiency (Bilirubin \> 50 µmol/L; SGOT/SGPT \> 10 x ULN) * Other current malignancies * Pregnancy (planned or existent), breast feeding